The ROE as of December 2024 (TTM) for Genelux Corporation (GNLX) is -105.05%

According to Genelux Corporation’s latest financial reports and current stock price. The company's current ROE is -105.05%. This represents a change of 239.45% compared to the average of -30.95% of the last 4 quarters.

Genelux Corporation (GNLX) Historical ROE (quarterly & annually)

How has GNLX ROE performed in the past?

The mean historical ROE of Genelux Corporation over the last ten years is 7.09%. The current -105.05% ROE has changed -1580.90% with respect to the historical average. Over the past ten years (40 quarters), GNLX's ROE was at its highest in in the June 2021 quarter at 80.88%. The ROE was at its lowest in in the March 2023 quarter at -535.45%.

Genelux Corporation (GNLX) ROE by Quarter and Year

Discovering the peaks and valleys of Genelux Corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Genelux Corporation (GNLX) Average ROE

How has GNLX ROE performed in the past?

The current ROE of Genelux Corporation (GNLX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Genelux Corporation (GNLX) ROE vs. Peers

How is GNLX’s ROE compared to its peers?

Genelux Corporation’s ROE is less than Comera Life Sciences Holdings, Inc. (67.46%), greater than Dyadic International, Inc. (-149.17%), greater than Cingulate Inc. (-113174.53%), greater than Monopar Therapeutics Inc. (-21731.73%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Acumen Pharmaceuticals, Inc. (-32.99%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than MoonLake Immunotherapeutics (-15.78%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than NewAmsterdam Pharma Company N.V. (-53.79%), less than Inventiva S.A. (524.89%), greater than Cullinan Oncology, Inc. (-26.54%), greater than Compass Therapeutics, Inc. (-32.37%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than Immuneering Corporation (-79.19%), greater than Centessa Pharmaceuticals plc (-52.22%), greater than Celcuity Inc. (-62.66%), greater than Ikena Oncology, Inc. (-39.59%),

Build a custom stock screener for Genelux Corporation (GNLX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genelux Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Genelux Corporation (GNLX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Genelux Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.